Table 3.
Mean CCA IMT (bilateral) related to background variables, traditional risk factors, laboratory tests and pharmacotherapy in univariate regression model of SLE cases with subgroups compared to healthy controls.
|
All SLE(n = 60) |
Controls(n = 60) |
LN(n = 20) |
APS(n = 20) |
Skin and joint(n = 20) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Variables | B | P | B | P | B | P | B | P | B | P | |
| Background variables | |||||||||||
| Age | –0.00 | 0.62 | 0.01 | <0.001 | –0.00 | 0.33 | –0.00 | 0.72 | –8.90 | 0.95 | |
| Female gender | 0.06 | 0.15 | –0.00 | 0.99 | 0.07 | 0.19 | 0.06 | 0.44 | –0.08 | 0.29 | |
| Duration of SLE | 0.00 | 0.06 | 0 | 0 | 0.00 | 0.62 | 0.00 | 0.34 | 0.00 | 0.48 | |
| SDI score | 0.03 | 0.01 | 0 | 0 | 0.00 | 0.91 | 0.04 | 0.14 | 0.03 | 0.39 | |
| SLEDAI-2K | 0.00 | 0.76 | 0 | 0 | –0.02 | 0.07 | –0.00 | 0.88 | 0.01 | 0.46 | |
| Traditional risk factors and laboratory data | |||||||||||
| BMI (kg/m2) | 0.00 | 0.79 | 0.01 | 0.05 | 0.00 | 0.58 | 0.01 | 0.60 | –0.01 | 0.63 | |
| Ever smoker (former or current) | 0.09 | 0.01 | 0 | 0 | 0.10 | 0.02 | –9.40 | 0.96 | 0.02 | 0.66 | |
| Systolic blood pressure | 2.84 | 0.97 | 0.00 | <0.001 | 0.00 | 0.74 | 0.02 | 0.95 | –3.17 | 1.00 | |
| Diastolic blood pressure | –0.00 | 0.59 | 0.00 | 0.02 | 0.00 | 0.86 | –0.00 | 0.44 | 0.00 | 0.87 | |
| Raynaud’s phenomenon | 0.05 | 0.15 | –0.03 | 0.33 | 0.01 | 0.84 | 0.15 | 0.03 | –0.04 | 0.28 | |
| Estimated glomerular filtration rate | 0.00 | 0.45 | 0 | 0 | 0.00 | 0.04 | –0.00 | 0.54 | 0.00 | 0.45 | |
| Total cholesterol | 0.02 | 0.22 | 0.05 | <0.001 | 0.01 | 0.64 | 0.07 | 0.10 | –0.00 | 0.83 | |
| High-density lipoprotein (HDL) | 0.03 | 0.30 | 0.06 | 0.09 | 0.02 | 0.74 | –0.09 | 0.17 | –0.01 | 0.78 | |
| Low-density lipoprotein (LDL) | 0.01 | 0.50 | 0.05 | <0.001 | 0.01 | 0.72 | 0.07 | 0.16 | –0.00 | 0.84 | |
| Triglycerides (TG) | 0.06 | <0.001 | 0.01 | 0.65 | 0.01 | 0.68 | 0.09 | 0.01 | 0.01 | 0.89 | |
| High-sensitivity CRP | 0.01 | 0.34 | 0.00 | 0.57 | 0.00 | 0.96 | 0.01 | 0.40 | –0.00 | 0.90 | |
| Medical treatment, ongoing | |||||||||||
| Antimalarial agents | –0.12 | 0.01 | 0 | 0 | NE | NE | –0.19 | 0.02 | 0.03 | 0.66 | |
| Glucocorticoid therapy | –0.02 | 0.51 | 0 | 0 | 0.05 | 0.15 | –0.06 | 0.36 | –0.03 | 0.39 | |
| Warfarin therapy | 0.07 | 0.05 | 0 | 0 | 0.05 | 0.50 | 0.05 | 0.49 | NE | NE | |
| Antiplatelet therapy | –0.05 | 0.16 | 0 | 0 | –0.01 | 0.84 | –0.14 | 0.06 | NE | NE | |
| Statin therapy | –0.01 | 0.88 | 0 | 0 | –0.16 | 0.04 | –0.00 | 0.96 | NE | NE | |
| DMARD therapy, n (%) | –1.76 | 0.76 | 0 | 0 | 0.01 | 0.88 | 0.14 | 0.03 | 0.10 | 0.001 | |
APS: antiphospholipid syndrome; CRP: C-reactive protein; BMI: body mass index; DMARDs: disease modifying anti-rheumatic drugs; LN: lupus nephritis; N/A: not applicable; NE: Not estimated; SDI: SLICC/ACR damage index; SLE: systemic lupus erythematosus.
Note: Statistically significant associations shown in bold.